Month: March 2022

FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launchExpanded the robust portfolio of data supporting the potential impact of FT218 on people living with narcolepsy with multiple presentations at World Sleep 2022Appointed Dr. Douglas Williamson as Chief Medical Officer and Brandi Robinson as Senior Vice President, Corporate AffairsExtended the maturity on $117.4 million of convertible notes to October 2, 2023Management to host a conference call today at 8:30 a.m. ETDUBLIN, Ireland, March 17, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2021. “Avadel...

– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific meetings in mid-2022 – – MuSK-CAART Investigational New Drug (IND) application cleared and Fast Track Designation granted by the U.S. Food and Drug Administration (FDA); planning to initiate first-in-human trial in 2022 – – Ended 2021 with $122.2 million in cash on hand to fund operations through 3Q 2023 – PHILADELPHIA, March 17, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided...

SHENZHEN, China, March 17, 2022 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading innovator in shared cloud computing and blockchain technology in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights:Total revenues were US$71.1 million, representing an increase of 18.6% from the previous quarter.Cloud computing and other internet value-added services (“Cloud computing and other IVAS”) revenues were US$44.7 million, representing an increase of 26.9% from the previous quarter.Subscription revenues were US$23.7 million, representing an increase of 4.3% from the previous quarter.Online advertising revenues, consisting primarily of revenues from mobile advertising, were US$2.8 million,...

CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing initiated in December 2021 for first-in-human clinical trials; initial clinical data expected by mid-2023 Portfolio advancement and expansion highlighted through multiple AACR abstract acceptances and HPK1 protein degrader collaboration with Mount Sinai CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2021. “Cullinan Oncology is dedicated to developing new standards of care...

Q4 2021 Revenue of $111.8 Million, up 16% sequentially Q4 2021 Adjusted EBITDA of $26.1 Million, flat sequentially FY 2021 Revenue and Adjusted EBITDA of $357.6 Million and $98.0 Million, up 131% and 84% Year-over-Year, respectively US GAAP Operating Loss of $13.8 Million and $56 Million for Q4 and FY 2021, respectivelyMIAMI, March 17, 2022 (GLOBE NEWSWIRE) — Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a vertically-integrated cannabis multi-state operator (MSO), is reporting financial results for the three and twelve months ended December 31, 2021. Unless otherwise noted, all results are presented in U.S. dollars. Jonathan Sandelman, Founder, Chairman and CEO of Ayr, said, “2021 was a transformative year for Ayr, with outsized revenue and Adjusted EBITDA growth, and an expanded operating footprint...

– Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder – Expanded use of Treprostinil Injection to include subcutaneous administration – Preparing to launch YUTREPIA in late-2022 pending final FDA approval – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., March 17, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for full-year ended December 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2021 financial results and provide a corporate update. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Last year, we achieved every goal we set by increasing sales of Treprostinil Injection, securing tentative approval of YUTREPIA,...